Detection of an atypical BCR::ABL1 fusion in a patient with secondary B-cell acute lymphoblastic leukemia/lymphoma following multiple myeloma treatment.
B-cell acute lymphoblastic leukemia/lymphoma
Fluorescence in situ hybridization
Gene fusion assay
Karyotype
Multiple myeloma
Philadelphia-positive
Tyrosine kinase inhibitors
Journal
Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
02
06
2022
revised:
09
01
2023
accepted:
16
03
2023
medline:
29
5
2023
pubmed:
27
3
2023
entrez:
26
3
2023
Statut:
ppublish
Résumé
Secondary hematologic malignancies, such as B-cell acute lymphoblastic leukemia/lymphoma (B-ALL), have been reported following multiple myeloma. Tyrosine kinase inhibitors have improved clinical outcomes of patients with Philadelphia-positive (Ph+) B-ALL. Therefore, recognition of the Ph chromosome in B-ALL patients is important for both prognosis and therapies. We present a case of a secondary Ph+ B-ALL following multiple myeloma that highlights a BCR::ABL1 fusion by a gene fusion assay to reveal a cryptic Ph chromosome, which may otherwise be missed by conventional cytogenetics and typical interphase fluorescence in situ hybridization.
Identifiants
pubmed: 36966724
pii: S2210-7762(23)00018-2
doi: 10.1016/j.cancergen.2023.03.005
pii:
doi:
Substances chimiques
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
30-32Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.